P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions

Drug Metabolism and Drug Interactions

Volumn 25, Issue 1, 2010, Pages 3-16

  Kumar, Yamsani Shravan ^a   Adukondalu, Devandla ^a   Sathish, Dharani ^a   Vishnu, Yamsani Vamshi ^a   Ramesh, Gannu ^a   Latha, Athukuri Bharagavi ^a   Reddy, Palem Chinna ^a   Sarangapani, Manda ^a   Rao, Yamsani Madhusudan ^a  

^a KAKATIYA UNIVERSITY   (India)

Author keywords

Cytochrome P 450 3A; In vitro; In vivo; Inhibitors; P Glycoprotein

Indexed keywords

ALKALOID DERIVATIVE; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CITRUS FRUIT EXTRACT; CURCUMA LONGA EXTRACT; CURCUMIN; CYTOCHROME P450 3A; DEMETHOXYCURCUMIN; DIDEMETHOXYCURCUMIN; GARLIC EXTRACT; GINSENG EXTRACT; GLYCOPROTEIN P; GRAPEFRUIT EXTRACT; HERBACEOUS AGENT; HORMONE DERIVATIVE; HYPERICUM PERFORATUM EXTRACT; IMMUNOSUPPRESSIVE AGENT; LOCAL ANESTHETIC AGENT; MACROLIDE; PEPTIDE DERIVATIVE; POMEGRANATE EXTRACT; PROTEINASE INHIBITOR; PYRROLE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR; UNINDEXED DRUG;

DRUG MECHANISM; DRUG METABOLISM; DRUG TRANSPORT; GRAPEFRUIT JUICE; HERB DRUG INTERACTION; HUMAN; HYPERICUM PERFORATUM; MULTIDRUG RESISTANCE; NONHUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HERB-DRUG INTERACTIONS; HUMANS; INTESTINAL ABSORPTION; INTESTINES; P-GLYCOPROTEIN; PHARMACEUTICAL PREPARATIONS; PLANT PREPARATIONS;

EID: 79951497709     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2010.006     Document Type: Review

References (84)

1. Agoram B, Woltosz WS, Bolger MB. Predicting the impact of physiological and biochemical processes on oral drug bioavailab (Pubitemid 32905355)
2. Zhang Y, Benet LZ. The gut as a barrier to drug absorption; combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001;40:159 - 63.
3. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identifi cation of glucocorticoid inducible cytochrome P-450 in intestinal mucosa of rats and man. J Clin Invest 1987;80: 1029 - 36. (Pubitemid 18075638)
4. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB. Identifi cation of rifampin-inducible P450 3A4 in human small bowel enterocytes. J Clin Invest 1992;90:1871 - 8.
5. Kolars JC, Awni WM, Watkins PB, Merion RM. First pass metabolism of cyclosporin by gut. Lancet 1991;338:1488 - 90.
6. Zhang Y, Guo X, Lin ET, Benet LZ. Overlapping substrate specifi cities of cytochrome P450 3A and P-glycoprotein for a novel cysteine protease inhibitor. Drug Metab Dispos 1998;26:360 - 6. (Pubitemid 28201247)
7. Benet LZ, Cummins CL. The drug effl ux-metabolism alliance: biochemical aspects. Adv Drug Del Rev 2001;50:S3 - 11. (Pubitemid 32905352)
8. Tandon VR, Kapoor B, Bano G, Guptha S, Gillani Z, Kour D. P-Glycoprotein: pharmacological relevance. Indian J Pharmacol 2006;38:13 - 24. (Pubitemid 43288648)
9. Wagner D, Spahn-Langguth H, Hanafy A, Koggel A, Langguth P. Intestinal drug effl ux: formulation and food effects. Adv Drug Del Rev 2001;50: 13 - 31. (Pubitemid 32905353)
10. Tsuji A, Tamai I. Carrier-mediated intestinal transport of drugs. Pharm Res 1996;13:963 - 77. (Pubitemid 26258994)
11. Chan LM, Lowes S, Hirst BH. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 2004;21:25 - 51. (Pubitemid 38050202)
12. Higgins CF, Callaghan R, Linton KJ, Rosenberg MF, Ford RC. Structure of the multidrug resistance P-glycoprotein. Sem Cancer Biol 1997;8:135 - 42. (Pubitemid 28041010)
13. Udeta K, Taguchi H, Morishima M. How does P-glycoprotein recognize its substrates ? Sem Cancer Biol 1997;8:151 - 15.
14. Dresser GK, Bailey DG. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur J Clin Invest 2003;33:10 - 6. (Pubitemid 37421611)
15. Varma MV, Ashokraj Y, Dey CS, Panchagula R. P-Glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003;48:347 - 59. (Pubitemid 36945333)
16. Udeta K, Taguchi H, Morishima M. How does P-glycoprotein recognize its substrates ? Sem Cancer Biol 1997;8:151 - 9. (Pubitemid 28041012)
17. Engman H. Intestinal barriers to oral drug absorption: cytochrome P450 3A and ABC-transport proteins. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 2003:296.
18. Deferme S, Van Gelder J, Augustijns P. Inhibitory effect of fruit extracts on p-glycoprotein related effl ux carriers: an in vitro screening. J Pharm Pharmacol 2002;54:1213 - 9.
19. Loo TW, Bartlett C, Clarke DM. Substrate-induced conformational changes in the transmembrane segments of human P-glycoprotein. Direct evidence for the substrate induced mechanism for drug binding. J Biol Chem 2003;274:13603 - 6. (Pubitemid 36799891)
20. Stephens RH, O'Neill CA, Warhurst A, Carlson GL, Rowland M. Kinetic profi ling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. J Pharmacol Exp Ther 2001;296:584 - 91. (Pubitemid 32112489)
21. Gombar VK, Polli JW, Humphreys JE, Wring SA, Serabjit- Singh CS. Predicting P-glycoprotein substrates by a quantitative structure activity relationship model. J Pharm Sci 2004;93: 957 - 68. (Pubitemid 38420406)
22. Lin JH. Drug-drug interactions mediated by inhibition and induction of P-glycoprotein. Adv Drug Del Rev 2003;55:53 - 81. (Pubitemid 36082882)
23. Anderle P, Huang Y, Sadee W. Intestinal membrane transport of drugs and nutrients: genomics of membrane transporters using expression microarrays. Eur J Pharm Sci 2004;21:17 - 24. (Pubitemid 38050201)
24. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlen-Ren P, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporin. Clin Pharmacol Ther 1997;62:248 - 60. (Pubitemid 27417790)
25. Johnson BM, Charman WN, Porter CJ. An in vitro examination of the impact of polyethylene glycol 400, Pluronic P85, and vitamin E D-alpha-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein effl ux and enterocyte-based metabolism in excised rat intestine. AAPS PharmSci 2002;4:1 - 11.
26. Doppenschmitt S, Spahn-Langguth H, Regardh CG, Langguth P. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: an approach using passive membrane permeability and affi nity to P glycoprotein. J Pharm Sci 1999;88:1067 - 72. (Pubitemid 29480601)
27. Lin JH. How signifi cant is the role of P-glycoprotein in drug absorption and brain uptake ? Drugs Today 2004;40:5 - 22. (Pubitemid 38270551)
28. Su SF, Huang JD. Inhibition of the intestinal digoxin absorption and exorption by quinidine. Drug Metab Dispos 1995;24: 142 - 7.
29. Verschraagen M, Koks CH, Schellens JH, Beijnen JH. P-Glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res 1999;40:301 - 6. (Pubitemid 29472055)
30. Salphati L, Benet LZ. Effect of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 1998;56:308 - 13. (Pubitemid 28246381)
31. Gramatte T, Oertel R. Intestinal secretion of intravenous talinolol is inhibited by luminal R-verapamil. Clin Pharmacol Ther 1999;66:239 - 45. (Pubitemid 29451755)
32. Khaliq Y, Gallicano K, Venance S, Kravcik S, Cameron DW. Effect of ketoconazole on ritonavir and saquinavir concentrations in plasma and CSF from patients infected with HIV. Clin Pharmacol Ther 2000;68:637 - 46. (Pubitemid 32059990)
33. Eichelbaum M, Greiner B, Fritz P, Kreichgauer H-P, von Richter O, Zundler J, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104: 147 - 52.
34. Hunter J, Hirst BH. Intestinal secretion of drugs. The role of P-glycoprotein and related drug effl ux systems in limiting oral drug absorption. Adv Drug Del Rev 1997;25:129 - 57. (Pubitemid 27288486)
35. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS. Identifi cation of glucocorticoid-inducible cytochromes P-450 in intestinal mucosa of rats and man. J Clin Invest 1987;80: 1029 - 36. (Pubitemid 18075638)
36. Clarke SJ. Human cytochromes P450 and their role in metabolism- based drug-drug interactions. In: Rodrigues AD, editor. Drug-drug interactions. New York: Marcel Dekker, 2002:55 - 88.
37. de Groot MJ, Ekins S. Pharmacore modeling of cytochromes P450. Adv Drug Del Rev 2002;54:367 - 83.
38. Lamba JK, Lin YS, Schuetz EG, Thummel KE. Genetic contributions to variable human CYP3A-mediated metabolism. Adv Drug Del Rev 2002;54:1271 - 94. (Pubitemid 35284253)
39. Wacher VJ, Silverman JA, Zhang Y, Benet LZ. Role of P glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998;87:1322 - 30.
40. Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P450 3A coordinately upregulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311 - 8. (Pubitemid 26066117)
41. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986;261:5051 - 60. (Pubitemid 17204301)
42. Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 1996;24:48 - 57.
43. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juicedrug interactions. Br J Clin Pharmacol 1998;46:101 - 10.
44. Fuhr U. Drug interactions with grapefruit juice. Extent, probable mechanism and clinical relevance. Drug Saf 1998;18:251 - 72. (Pubitemid 28177290)
45. Guo LQ, Taniguchi M, Xiao YQ, Baba K, Ohta T, Yamazoe Y. Inhibitory effect of natural furanocoumarins on human microsomal cytochrome P450 3A activity. Jpn J Pharmacol 2000; 82:122 - 9. (Pubitemid 30153593)
46. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000;294:88 - 95. (Pubitemid 30434674)
47. Patel J, Buddha B, Dey S, Pal D, Mitra AK. In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in Pgp and CYP3A4 activity. Am J Ther 2004;11:262 - 77.
48. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St. John's wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000;66:133 - 9. (Pubitemid 30077858)
49. Bray BJ, Perry NB, Menkes DB, Rosengren RJ. St. John's wort extract induces CYP3A and CYP2E1 in the Swiss Webster mouse. Toxicol Sci 2002;66:27 - 33. (Pubitemid 34202026)
50. Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002;71:1579 - 89. (Pubitemid 34808718)
51. Karch AM. The grapefruit challenge: the juice inhibits a crucial enzyme, with possibly fatal consequences. Am J Nurs 2004;104:33 - 5.
52. Hidaka M, Okumura M, Fujita K, Ogikubo T, Yamasaki K, Iwakiri T, et al. Effects of pomegranate juice on human cytochrome P450 3a (cyp3a) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos 2005;33:644 - 8. (Pubitemid 40593878)
53. Pom: the new juice in town. Consumer Reports 2005;July:1 - 4.
54. Bailey DG, Malcolm J, Arnold O, Spence JD. Grapefruit juicedrug interactions. Br J Clin Pharmacol 1998;46:101 - 10.
55. Shravan KY, Ramesh G, Adukondalu D, Vamshi VY, Chinna RP, Shiva KR, et al. Effect of silymarin and pomegranate pretreatment on intestinal transport of buspirone across rat intestine. Acta Pharm Sci 2009;51:289 - 96.
56. Fugh BA, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001;52:587 - 95.
57. Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002;34:234 - 8. (Pubitemid 34028358)
58. Berginc K, Trontelj J, Kristl A. The infl uence of aged garlic extract on the uptake of saquinavir and darunavir into HepG2 cells and rat liver slices. Drug Metab Pharmacokinet 2010;25:307 - 13.
59. Hajda J, Rentsch KM, Gubler C, Steinert H, Steiger B, Fattinger K. Garlic extract induces intestinal P-glycoprotein, but exhibits no effect on intestinal and hepatic CYP3A4 in humans. Eur J Pharm Sci 2010;41:729 - 35.
60. Wana CK, Tse AK, Yu ZL, Zhu GY, Wang H, Fong DW. Inhibition of cytochrome P4503A4 activity by schisandrol A and gomisin A isolated from Fructus schisandrae chinensis. Phytomedicine 2010;17:702 - 5.
61. Vella S, Floridia M. Saquinavir. Clinical pharmacology and effi cacy. Clin Pharmacokinet 1998;34:189 - 201. (Pubitemid 28112398)
62. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998;35:275 - 91. (Pubitemid 28491214)
63. Li X, Chan WK. Transport, metabolism and elimination mechanisms of anti-HIV agents. Adv Drug Deliv Rev 1999;39:81 - 103. (Pubitemid 29430231)
64. Malaty LI, Kuper JJ. Drug interactions of HIV protease inhibitors. Drug Saf 1999;20:147 - 69. (Pubitemid 29101279)
65. Williams GC, Sinko PJ. Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev 1999;39:211 - 38. (Pubitemid 29430237)
66. Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000;92:1295 - 302. (Pubitemid 30662093)
67. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152 - 62.
68. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human " MDR1 " gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 1987;84:3004 - 8. (Pubitemid 17064766)
69. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular and pharmacological aspects of multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361 - 98. (Pubitemid 29222564)
70. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62:385 - 427. (Pubitemid 23237876)
71. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003;42:59 - 98. (Pubitemid 36092258)
72. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St. John's wort. Lancet 2000;355:547 - 8.
73. Roby CA, Anderson GD, Kantor E, Dryer DA, Burstein AH. St. John's wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000;67:451. (Pubitemid 30327483)
74. Durr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, et al. St. John's wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000;68:598 - 604. (Pubitemid 32059985)
75. Perloff MD, Von Moltke LL, Stormer E, Shader RI, Greenblatt DJ. Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001;134:1601 - 8. (Pubitemid 34038092)
76. Chieli E, Romiti N, Cervelli F, Tongiani R. Effects of fl avonols on P-glycoprotein activity in cultured rat hepatocytes. Life Sci 1995;57:1741 - 51.
77. Scambia G, Ranelletti FO, Panici PB, De Vincenzo R, Bonanno G, Ferrandina G, et al. Quercetin potentiates the effect of adriamycin in a multidrug-resistant MCF-7 human breast-cancer cell line: P-glycoprotein as a possible target. Cancer Chemother Pharmacol 1994;34:459 - 64. (Pubitemid 24306043)
78. Shapiro AB, Ling V. Effect of quercetin on Hoechst 33342 transport by purifi ed and reconstituted P-glycoprotein. Biochem Pharmacol 1997;53:587 - 96. (Pubitemid 27149553)
79. Ampasavate C, Sotanaphun U, Phattanawasin P, Piyapolrungroj N. Effects of Curcuma spp. on P-glycoprotein function. Phytomedicine 2010;17:506 - 12.
80. El-Readi MZ, Hamdan D, Farrag N, El-Shazly A, Wink M. Inhibition of P-glycoprotein activity by limonin and other secondary metabolites from Citrus species in human colon and leukaemia cell lines. Eur J Pharm Sci 2010;626:139 - 45.
81. Leslie EM, Deeley RG, Cole SP. Toxicological relevance of the multidrug resistance protein 1 MRP1 (ABCC1) and related transporters. Toxicology 2001;167:3 - 23. (Pubitemid 32830943)
82. Mitra AK, Patel J. Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. Pharmacogenomics 2001;2:401 - 15. (Pubitemid 33120900)
83. Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000;97:7500 - 2. (Pubitemid 30431492)
84. Fiebich BL, Holli A, Lieb K. Inhibition of substance P-induced cytokine synthesis by St. John's wort extracts. Pharmacopsychiatry 2001;34:S26 - 8.